Page last updated: 2024-08-21

quinazolines and decitabine

quinazolines has been researched along with decitabine in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's6 (75.00)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Díaz-Montero, CM; Estecio, M; Issa, JP; Mao, L; Montero, AJ; Shen, L; Youssef, EM1
Berkova, Z; Koblas, T; Leontovyč, I; Pektorova, L; Saudek, F; Zacharovova, K1
Cao, HX; Feng, JF; Li, XY; Ma, R; Wu, JQ; Wu, JZ; Zhong, YJ1
Chen, PJ; Huang, GB; Li, B; Lou, YF; Luo, XY; Yu, XR; Zheng, DQ; Zou, ZZ1
Erba, HP1
Barat, C; Dental, C; Ouellet, M; Proust, A; Tremblay, MJ1
Heldermon, CD; Kitada, K; Koyama, M; Meacham, AM; Pacak, CA; Santostefano, KE; Tachibana, D; Terada, N; Waldrop, SM; Watanabe, N; Yokoyama, A1

Reviews

1 review(s) available for quinazolines and decitabine

ArticleYear
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
    Leukemia research, 2015, Volume: 39, Issue:2

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones

2015

Other Studies

7 other study(ies) available for quinazolines and decitabine

ArticleYear
Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.
    Cancer biology & therapy, 2006, Volume: 5, Issue:11

    Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Decitabine; Dinucleoside Phosphates; DNA Methylation; DNA Primers; Epigenesis, Genetic; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Organ Specificity; Quinazolines; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction

2006
The effect of epigenetic factors on differentiation of pancreatic progenitor cells into insulin-producing cells.
    Transplantation proceedings, 2011, Volume: 43, Issue:9

    Topics: Azacitidine; Azepines; C-Peptide; Cell Culture Techniques; Cell Differentiation; Decitabine; Epigenesis, Genetic; Humans; Hydroxamic Acids; Immunohistochemistry; Insulin-Secreting Cells; Islets of Langerhans; Keratin-19; Models, Biological; Models, Genetic; Pancreas; Pyrroles; Quinazolines; Stem Cells; Transcription Factors

2011
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Oncology reports, 2013, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines

2013
News products to avoid.
    Prescrire international, 2014, Volume: 23, Issue:148

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur

2014
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases

2014
HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.
    Journal of immunology (Baltimore, Md. : 1950), 2017, 02-01, Volume: 198, Issue:3

    Topics: Acetamides; Azacitidine; Azepines; Blood-Brain Barrier; Bryostatins; Cell Adhesion; Cell Adhesion Molecules; Cell Movement; Cells, Cultured; Chemokine CCL2; Cytokines; Decitabine; HIV-1; Humans; Inflammation; Intercellular Adhesion Molecule-1; Leukocytes; Phorbol Esters; Quinazolines; Receptors, Cell Surface; Virus Latency

2017
Generation of Induced Pluripotent Stem Cells from a Female Patient with a Xq27.3-q28 Deletion to Establish Disease Models and Identify Therapies.
    Cellular reprogramming, 2020, Volume: 22, Issue:4

    Topics: Cell Differentiation; Cells, Cultured; Child, Preschool; Chromosome Deletion; Chromosomes, Human, X; Decitabine; Developmental Disabilities; Female; Fragile X Mental Retardation Protein; Fragile X Syndrome; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Induced Pluripotent Stem Cells; Intellectual Disability; Quinazolines

2020